Sigyn Therapeutics has announced the appointment of Michael Ryan to its Board of Directors, bringing significant expertise in medical technology and investment strategy to the company's leadership. Ryan, a Founding Director of Irrus Investments, Ltd., has an extensive background in supporting early-stage technology and life science companies. Through Irrus Investments, he has been instrumental in investing over $50 million across 40 early-stage companies in Ireland, the United Kingdom, Sweden, and the United States.
With a professional history that includes serving as CEO of Sedana Medical and leading Artema Medical AB, Ryan brings a wealth of experience in medical technology entrepreneurship. He holds a B.Eng in Mechanical Engineering and a Masters in Industrial Engineering from University College Dublin. Sigyn Therapeutics CEO Jim Joyce emphasized Ryan's potential contributions, noting that his expertise will help the company advance its mission of developing blood purification technologies designed to save lives. Ryan expressed enthusiasm about joining the board, highlighting the company's compelling strategy to address significant global health challenges.
The company is currently developing Sigyn Therapy, a blood purification technology with demonstrated capabilities to reduce viral pathogens, bacterial toxins, and pro-inflammatory cytokines from human blood plasma. The technology shows potential for treating life-threatening conditions such as viruses, antibiotic-resistant bacterial infections, endotoxemia, and sepsis. Sigyn Therapeutics is also developing an oncology pipeline, including platforms like ImmunePrepTM, ChemoPrepTM, and ChemoPureTM, which aim to enhance immunotherapeutic and chemotherapeutic treatments while potentially reducing toxicity.
Ryan's appointment represents a strategic move to strengthen Sigyn Therapeutics' leadership and potentially accelerate the development of its innovative medical technologies. The company's focus on addressing critical unmet medical needs through blood purification technologies positions it in a growing field of medical innovation. The addition of Ryan's investment and operational experience could provide valuable guidance as the company advances its clinical development programs and seeks to bring its technologies to patients facing life-threatening conditions.
